Posters

Two different phakic posterior chamber IOLs for the correction of myopia or myopic astigmatism: safety and efficacy

Poster Details

First Author: S.Taneri GERMANY

Co Author(s):    A. Rost   S. Kießler   B. Dick              

Abstract Details

Purpose:

To compare adverse events, refractive, and visual outcomes of Implantable Phakic Contact Lens (IPCL, Care Group, Gujarat, India) to Implantable Collamer Lenses (ICL, Staar Surgical, Lake Forest, CA, USA) for correction of high myopia and myopic astigmatism.

Setting:

Center for Refractive Surgery, Eye Department at St. Francis Hospital Muenster, Germany

Methods:

Observational consecutive case series. Inclusion criteria: myopic and myopic astigmatic eyes with implantation of spherical or toric monofocal IPCL V 2.0 or ICL V 4.0 for full correction in which high myopia and / or corneal conditions have excluded a laser-based refractive procedure. Exclusion criteria: Internal anterior chamber depth <2.8 mm, central endothelial cell count < 2000/cm2.One hundred-nineteen eyes were included (43 eyes IPCL).

Results:

No adverse events except postoperative pressure spikes occurred within the first 3 months. At 3 months, mean spherical equivalent refraction was +0.06+/-0.38D (range: -0.63 to +1.25D) after IPCL implantation and +0.06+/-0.44D (range: -1.13 to +1.88D) after ICL implantation. Mean cylinder was -0.38 +/- 0.44D (range: 0 to -2.75D) and -0.38+/-0.41D (range: 0 to -1.75D) with IPCL and ICL, respectively. Mean uncorrected distance visual acuity (UDVA) was 1.13 (decimal scale) and 1.04 with ICPL and ICL, respectively. Mean efficacy index was 1.13 and 1.16 with IPCL and ICL, respectively. Mean safety index was 1.27 and 1.31 with IPCL and ICL, respectively.

Conclusions:

We found equally good visual and refractive outcomes with IPCL and ICL for the correction of high and moderate myopia with or without astigmatism. There is no need for nomogram adjustment when transitioning from ICL to IPCL. However, longer follow-up is warranted to determine stability of results and possible long-term adverse events.

Financial Disclosure:

None